US Bancorp
ADAP

US Bancorp’s Adaptimmune Therapeutics ADAP Stock Holding History

US Bancorp’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,058
Closed -$825 – 3970
2023
Q3 		$825 Hold
1,058
– – ﹤0.01% 3798
2023
Q2 		$979 Buy
+1,058
New +$1.26K ﹤0.01% 3810
2022
Q4 		– Sell
-16,049
Closed -$18K – 4133
2022
Q3 		$18K Buy
16,049
+14,939
+1,346% +$27.4K ﹤0.01% 3057
2022
Q2 		$2K Sell
1,110
-9,367
-89% -$16.1K ﹤0.01% 3787
2022
Q1 		$22K Buy
10,477
+6,028
+135% +$16.3K ﹤0.01% 3012
2021
Q4 		$17K Sell
4,449
-1,280
-22% -$5.83K ﹤0.01% 3186
2021
Q3 		$29K Buy
5,729
+4,590
+403% +$20.6K ﹤0.01% 2922
2021
Q2 		$5K Sell
1,139
-188
-14% -$912 ﹤0.01% 3592
2021
Q1 		$7K Sell
1,327
-109
-8% -$624 ﹤0.01% 3398
2020
Q4 		$7K Sell
1,436
-471
-25% -$2.56K ﹤0.01% 3291
2020
Q3 		$15K Buy
1,907
+549
+40% +$4.8K ﹤0.01% 2923
2020
Q2 		$14K Sell
1,358
-615
-31% -$3.86K ﹤0.01% 2965
2020
Q1 		$5K Buy
+1,973
New +$6.55K ﹤0.01% 3230

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

US Bancorp's ADAP Position: Q4 2023 in Review

US Bancorp sold out of Adaptimmune Therapeutics (ADAP) in Q4 2023, closing a stake of 1,058 shares — an estimated $825 sold.

US Bancorp first reported a position in ADAP in Q1 2020 and held it in 13 quarters. The position peaked at $29K in Q3 2021. 79 funds tracked by Wall St. Rank hold ADAP as of Q4 2023.

  • US Bancorp reported no remaining Adaptimmune Therapeutics position as of Q4 2023 after selling out during the quarter.
  • US Bancorp sold 1,058 Adaptimmune Therapeutics shares in Q4 2023, an estimated $825.
  • US Bancorp first reported a position in Adaptimmune Therapeutics in Q1 2020 and held it in 13 quarters.
  • US Bancorp's Adaptimmune Therapeutics position peaked at $29K in Q3 2021.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2023.

Based on US Bancorp's 13F filing for Q4 2023, filed 9 Feb 2024.